Novavax, Inc. (NVAX) Closed at $1.03

Cornelia Mascio
Mag 20, 2017

When it comes to the Analysis of a Stock, Price Target plays a vital role. To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road. Piermont Capital Management Inc. increased its position in Novavax by 9.2% in the third quarter. Piermont Capital Management Inc. now owns 158,788 shares of the biopharmaceutical company's stock worth $330,000 after buying an additional 13,370 shares in the last quarter.

Novavax, Inc. (NASDAQ:NVAX) share price decreased in the last trading session with a previous 52-week high of $8.49. Two Sigma Securities LLC bought a new stake in Novavax during the third quarter worth $751,000. Finally, JPMorgan Chase & Co. increased its position in shares of Novavax by 110.5% in the third quarter. JPMorgan Chase & Co. now owns 3,570,243 shares of the biopharmaceutical company's stock valued at $7,427,000 after buying an additional 1,873,773 shares in the last quarter. Hedge funds and other institutional investors own 60.36% of the company's stock.

02/28/2017 - Novavax, Inc. had its "neutral" rating reiterated by analysts at Chardan Capital. (NVAX), the 200 simple moving average (SMA) is considered a key indicator by traders and market analysts for determining the overall long-term trend. The stock exchanged hands with 7.49 million shares contrast to its average daily volume of 7.95 million shares. The stock appeared -87.87% below its 52-week highs and is up 24.10% for the last five trades. The stock's market cap is $308.03 million.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Monday, May 8th.

Taking a broader look brokerage firms' analysts on the street with an expectant view have Novavax Inc (NASDAQ:NVAX) high price target of $12 and with a conservative view have low price target of $0.9. Novavax had a negative net margin of 1,908.41% and a negative return on equity of 189.14%. The Higher end of the revenue forecast is $6.6 Million, while the Lower end of the forecast is $4.5 Million. The company is estimating to achieve earnings per share (EPS) growth of 17.00% in this year. The firm's revenue for the quarter was down 7.7% compared to the same quarter previous year.

ICON Public Limited Company (NASDAQ:ICLR) and Novavax, Inc. This Beta value of Novavax, Inc. "(NVAX)" was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem.

NVAX has been the subject of several research analyst reports. Cantor Fitzgerald reissued a "hold" rating and issued a $2.00 price target on shares of Novavax in a research note on Friday, January 20th. Analysts reported that the Price Target for Novavax, Inc. might touch $12 high while the Average Price Target and Low price Target is $3.7 and $1.5 respectively. (NASDAQ:NVAX), whilst 1 of which rate the stock "Buy", 0 "Outperform", 0 "Underperform", 0 "Sell", while 6 "Hold". The stock now has a Market Cap of $73.33B. The stock is now trading -4.23% below its SMA 50 and 5.49% above its SMA 200.

Debt to Equity ratio stands at 0 while Long Term Debt To Equity Ratio flashes the value of 0. Earnings per share serves as an indicator of a company's profitability. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Future earnings predictions are perhaps the most essential input when trying to value a company.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE